Please enable JS

ARTICLES & TESTIMONIALS

GHLF/50-SN activity at FDA Arthritis Advisory Committee Meeting July 12th & July 13th

Jul 18/50SN Staff/ Events

On July 12th and 13th the Arthritis Advisory Committee, or AAC, met at the FDA to participate in a hearing about two potential biosimilar drugs. GHLF provided commentary to speak on behalf of the 50-State Network. What is the AAC? The AAC, created by the FDA, reviews and evaluates data concerning the safety and efficacy […]

READ MORE

Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

Jul 18/50SN Staff/ GHLF in the news

The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.

READ MORE

July 12th – GHLF testimony and recommendation to FDA on proposed biosimilar to HUMIRA (adalimumab)

Jul 15/50SN Staff/ FDA Testimony Letters and Testimony

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

READ MORE

July 13th – GHLF FDA Arthritis Advisory Committee comments on proposed biosimilar to ENBREL (etanercept)

Jul 15/50SN Staff/ FDA Testimony Letters and Testimony

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

READ MORE

FDA advisory committee unanimously recommends approval of biosimilar to Enbrel – Perspective by Seth Ginsberg

Jul 15/50SN Staff/ GHLF in the news

The overall aim of biosimilar is to help contribute toward the reduction of cost for patients.

READ MORE